Trials / Completed
CompletedNCT00888004
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AFQ056 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-08-01
- First posted
- 2009-04-24
- Last updated
- 2016-04-19
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00888004. Inclusion in this directory is not an endorsement.